Barclays believes the FDA’s warning letter to Globus Medical “should be manageable” and should not interfere with the company’s robot or implant sales. The firm does not expect the letter to prevent Globus from meeting or exceeding its operating goals. It views the selloff on the news as an “attractive buying opportunity” and reiterates an Overweight rating on the name with a $93 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $93 from $85 at Barclays
- Arm upgraded, Molson Coors downgraded: Wall Street’s top analyst calls
- Wells upgrades Globus Medical on better-than-expected NuVasive integration
- Globus Medical upgraded to Overweight from Equal Weight at Wells Fargo
- Globus Medical sees FY24 EPS $2.80-$2.90, consensus $2.82